StopDown
Analysis · 21 February 2026Attox Research Laboratoriesrapid antibiotic testing for hospitals

Attox Research Laboratories develops faster antibiotic testing for hospitals

By · Editor ·

  • Attox Research Laboratories builds faster and more accessible antibiotic susceptibility testing (AST) solutions for hospitals
  • Their product, Bactolizer, reduces the time needed to determine which antibiotics work against a specific infection
  • Faster testing helps doctors choose the right treatment sooner, reducing hospital stays and misuse of broad-spectrum antibiotics

What happened

  • Attox Research Laboratories is an Indian medical diagnostics startup working on faster antibiotic susceptibility testing (AST) solutions for hospitals.
  • Their flagship product, Bactolizer, aims to cut down the time it takes to get AST results compared to traditional methods.
  • Traditional AST tests can take 24 to 72 hours, but faster results allow doctors to choose the most effective antibiotic earlier.
  • This helps patients recover faster, reduces hospital stays, and lowers the unnecessary use of broad-spectrum antibiotics.
  • The company is focusing on clinical validation studies and regulatory approvals to prove the product's reliability.
  • They are also engaging with physicians to ensure the technology is adopted in hospitals.

Why it matters

  • Speed in antibiotic testing is critical in intensive care settings, where delays can be life-threatening.
  • Faster testing allows doctors to quickly identify which antibiotics are not working and switch to more targeted treatments.
  • This can directly reduce the risk of death in patients with severe infections like sepsis.
  • The team emphasizes the importance of patience, precision, and persistence in building a medical diagnostics company.

The business

  • Attox Research Laboratories focuses on developing faster and more accessible antibiotic susceptibility testing (AST) solutions for hospitals.
  • Their product, Bactolizer, is designed to reduce the time needed to determine which antibiotics work against a specific infection.
  • The company is targeting hospitals and healthcare providers that need reliable and efficient diagnostic tools.
  • They are running clinical validation studies to prove the product's reliability and comparing it with standard AST methods.
  • The goal is to obtain regulatory approvals and show hospitals the cost and efficiency benefits through real data.

In their words

“Focus on solving meaningful problems that have long term impact and make sure to learn about regulatory pathways early and above all, be resilient, because deep-tech and healthcare startups demand a level of patience.”Attox Research Laboratories team, startup founders

Words to know

AST
Antibiotic Susceptibility Testing, a method used to determine which antibiotics will work against a specific bacterial infection.
broad-spectrum antibiotics
Antibiotics that are effective against a wide range of bacteria, often used as a precaution when the exact infection is unknown.
sepsis
A life-threatening condition that arises when the body's response to an infection causes widespread inflammation and organ failure.
antimicrobial resistance
A phenomenon where bacteria become resistant to antibiotics, making infections harder to treat.

The numbers around it

Healthcare & Life Sciences in February 2026: 18 rounds with a disclosed amount, $66.5 million in all; the biggest was Pandorum Technologies ($18M). Every sector this year →

Read it as a card in the app

All startup news on 21 February 2026 →

Is this Attox Research Laboratories? Get your “Featured on StopDown” badge →